Physician profile
Alicia W Wright
NPI 1619237880
$3,322.64
in general payments reported to CMS, 2019-2025
33 companies · $572 in 2025
The $572 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $360 · 2021: $584 · 2022: $513 · 2023: $389 · 2024: $496 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,456.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $399.10 | 2019-2025 | |
| Daiichi Sankyo INC. | $298.50 | 2019-2025 | Injectafer |
| Mayne Pharma Commercial LLC | $258.02 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $257.99 | 2019-2025 | |
| Glaxosmithkline, LLC. | $256.20 | 2019-2024 | Pediarix, Bexsero, Rotarix |
| Pfizer INC. | $242.63 | 2019-2024 | |
| Hologic Sales and Service, LLC | $198.07 | 2019-2025 | Acessa Provu System, Myosure Tissue Removal Device, Novasure |
| Novo Nordisk INC | $187.56 | 2020-2024 | Wegovy |
| Shield Therapeutics INC | $181.70 | 2023-2025 | Accrufer |
| Exeltis, USA INC. | $156.67 | 2019-2025 | Slynd |
| Avion Pharmaceuticals | $114.43 | 2020-2022 | |
| Mylan Pharmaceuticals INC. | $113.79 | 2019-2022 | |
| Organon LLC | $95.75 | 2022-2025 | Jada System |
| Biogen, INC. | $55.48 | 2025 | Zurzuvae |
| Coopersurgical, INC. | $53.36 | 2021-2024 | Paragard T 380a, Paragard T 380a |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $52.51 | 2019-2021 | |
| Millicent US INC | $50.60 | 2025 | Intrarosa, Femlyv, Femring |
| Scynexis, INC. | $45.03 | 2022 | |
| Agile Therapeutics, INC. | $37.67 | 2021 | |
| Medtronic, INC. | $28.23 | 2023 | Truclear |
| Allergan, INC. | $25.91 | 2019 | |
| Amag Pharmaceuticals, INC. | $24.46 | 2019 | |
| Sumitomo Pharma America, INC. | $24.10 | 2024 | Myfembree |
| Becton, Dickinson and Company | $20.52 | 2025 | Hemosphere |
| Channel Medsystems, INC. | $20.50 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $20.48 | 2024 | Exparel |
| Merck Sharp & Dohme LLC | $19.31 | 2025 | Gardasil 9 |
| Roche Diagnostics Corporation | $18.45 | 2019 | |
| Bausch Health US, LLC | $14.28 | 2021 | |
| Astellas Pharma US INC | $13.44 | 2021 | |
| Lilly USA, LLC | $13.34 | 2024 | Zepbound |
| Boston Scientific Corporation | $12.73 | 2019 | |
| Amgen INC. | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alicia Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.